Literature DB >> 32423910

Acral vascular syndrome during an immune checkpoint inhibitor.

Patrick O'Connor1, Pooja Bhadbhade2, Qamar Khan3, Stephen Williamson4.   

Abstract

Immune checkpoint inhibitors, including antiprogrammed death cell protein 1 (anti-PD-1) and anti cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), have been associated with a range of autoimmune-related side effects since their introduction in cancer treatment. Small vessel digital necrosis, referred to as the acral vascular syndrome, is a rare but serious complication that can result in loss of digits. Here we present a case report of acral vascular syndrome and review possible aetiologies. A 45- year-old woman with invasive ductal carcinoma of the left breast presented to the emergency department during neoadjuvant treatment with carboplatin, docetaxel and pembrolizumab with complaints of severe pain in her right third digit. She had physical findings consistent with ischaemic necrosis and gangrene of the distal phalanx. Angiography demonstrated Raynaud's phenomenon in the distal portion of the digits. Laboratory testing showed a weakly positive RNA polymerase III antibody level. Her case resulted in surgical amputation of her affected digit after partial resolution of symptoms with prednisone, vasodilators and antibiotics. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  oncology; unwanted effects / adverse reactions; vasculitis

Mesh:

Substances:

Year:  2020        PMID: 32423910      PMCID: PMC7239533          DOI: 10.1136/bcr-2019-233463

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

Authors:  Ami A Shah; Antony Rosen; Laura Hummers; Fredrick Wigley; Livia Casciola-Rosen
Journal:  Arthritis Rheum       Date:  2010-09

2.  Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Authors:  Marie Kostine; Léa Rouxel; Thomas Barnetche; Rémi Veillon; Florent Martin; Caroline Dutriaux; Léa Dousset; Anne Pham-Ledard; Sorilla Prey; Marie Beylot-Barry; Amaury Daste; Marine Gross-Goupil; Julie Lallier; Alain Ravaud; Edouard Forcade; Bernard Bannwarth; Marie-Elise Truchetet; Christophe Richez; Nadia Mehsen; Thierry Schaeverbeke
Journal:  Ann Rheum Dis       Date:  2017-11-16       Impact factor: 19.103

3.  Acute Lower Limb Ischaemia and Diabetes in a Patient Treated with Anti-PD1 Monoclonal Antibody for Metastatic Melanoma.

Authors:  Benjamin Thoreau; Flora Gouaillier-Vulcain; Laurent Machet; Christine Mateus; Caroline Robert; Nicole Ferreira-Maldent; François Maillot; Bertrand Lioger
Journal:  Acta Derm Venereol       Date:  2017-03-10       Impact factor: 4.437

4.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

5.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

6.  Rheumatic Syndromes Associated With Immune Checkpoint Inhibitors: A Single-Center Cohort of Sixty-One Patients.

Authors:  Michael D Richter; Cynthia Crowson; Lisa A Kottschade; Heidi D Finnes; Svetomir N Markovic; Uma Thanarajasingam
Journal:  Arthritis Rheumatol       Date:  2019-01-28       Impact factor: 10.995

Review 7.  Rheumatic immune-related adverse events in patients on anti-PD-1 inhibitors: Fasciitis with myositis syndrome as a new complication of immunotherapy.

Authors:  J Narváez; P Juarez-López; J LLuch; J A Narváez; R Palmero; X García Del Muro; J M Nolla; E Domingo-Domenech
Journal:  Autoimmun Rev       Date:  2018-08-10       Impact factor: 9.754

8.  Ipilimumab induced digital vasculitis.

Authors:  Amrita Padda; Elena Schiopu; Justin Sovich; Vincent Ma; Ajjai Alva; Leslie Fecher
Journal:  J Immunother Cancer       Date:  2018-02-12       Impact factor: 13.751

9.  Digital ischemia associated with cancer: results from a cohort study.

Authors:  Maëlle Le Besnerais; Sébastien Miranda; Nicole Cailleux; Nicolas Girszyn; Isabelle Marie; Hervé Lévesque; Ygal Benhamou
Journal:  Medicine (Baltimore)       Date:  2014-08       Impact factor: 1.889

10.  Immune checkpoint inhibitor-related acral vasculitis.

Authors:  Thibault Comont; Vincent Sibaud; Loïc Mourey; Pierre Cougoul; Odile Beyne-Rauzy
Journal:  J Immunother Cancer       Date:  2018-11-16       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.